Luye Pharma Group

• NCT07391566

  Phase 1/2, Not yet recruiting, 99 people, 6 Feb 2026

• NCT06467409

  Phase 2, Status unknown, 150 people, 21 Jun 2024

• NCT06204120

  Phase 2, Completed, 150 people, 12 Jan 2024

• NCT06095427

  Phase 1, Completed, 300 people, 23 Oct 2023

• Comparative Efficacy, Safety, PK, and Immunogenicity Study

  Phase 3, Status unknown, 392 people, 10 May 2023

• NCT04973722

  Phase 1, Status unknown, 168 people, 22 Jul 2021

• NCT04859569

  Phase 3, Status unknown, 850 people, 26 Apr 2021

• NCT02603770

  Phase 1, Completed, 20 people, 13 Nov 2015

Sources: clinicaltrials.gov